Time to market for lpilimumab

Ipilimumab (Ipilimumab) was launched overseas in 2011. It is an immunotherapy drug developed and approved by the American pharmaceutical company Bristol-Myers Squibb. The approval of this drug is regarded as a major breakthrough in the field of tumor immunotherapy because it is the first CTLA-4 (cytotoxic T lymphocyte antigen4) inhibitor approved by the U.S. Food and Drug Administration (FDA).

The launch of ipilimumab marks an important advance in the field of immunotherapy, as it provides a new way to treat some malignancies, especially malignant melanoma (melanoma). In the past, melanoma was often considered a difficult-to-treat cancer type, but the approval of ipilimumab gives patients more treatment options. In addition, ipilimumab was later approved to treat other cancer types, including advanced colorectal cancer.

The successful launch of ipilimumab has also stimulated widespread interest in immunotherapy, prompting more research and clinical trials to develop more immunotherapy drugs and improve the survival and quality of life of cancer patients. Its launch demonstrates the potential of immunotherapy in cancer treatment and is therefore considered a major innovation in the field of cancer treatment.

It is important to note that many other immunotherapy drugs have been approved since ipilimumab became available, and the field continues to evolve. Different immunotherapy drugs may have a positive impact on patients with different types of cancer, so treatment options often need to be individualized and managed based on the patient's specific situation and cancer type.

Ipilimumab is not currently available in China, so patients cannot purchase it domestically and can only purchase it through overseas purchase channels. There are only original drugs of Ipilimumab abroad, mainly Turkish original drugs and Bristol-Myers Squibb original drugs. The price of Turkish original drugs is around 12,000 yuan, and the specification is 50mg /10ml; Bristol-Myers Squibb -The price of Bristol-Myers Squibb original drug is about 11,700 yuan, and the specifications are also 50mg/10ml, both have the same medicinal ingredients.